- Constrained formation of 2-(1-(arylimino)ethyl)-7-arylimino-6,6-dimethylcyclopentapyridines and their cobalt(ii) chloride complexes: Synthesis, characterization and ethylene polymerization
-
A series of 2-(1-(arylimino)ethyl)-7-arylimino-6,6-dimethylcyclopentapyridine derivatives (L1-L5) was synthesized, and individually reacted with cobalt(ii) chloride to form the corresponding cobalt chloride complexes (C1-C4). These compounds were characte
- Ba, Junjun,Du, Shizhen,Yue, Erlin,Hu, Xinquan,Flisak, Zygmunt,Sun, Wen-Hua
-
-
Read Online
- METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS
-
The invention relates to a method of producing a WEE1 inhibitor of formula (1A) useful in the treatment of pathological conditions characterized by excessive cell proliferation, such as cancer. In some embodiments, the invention relates to methods for producing intermediate compounds of formulas (3), (5) and (6) as defined in the description.
- -
-
-
- AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
-
Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein "R1", "RA-1", "R2", "R3", and "Het" are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
- -
-
-
- IRAK4 INHIBITING AGENTS
-
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
- -
-
-
- AMIDE COMPOUND
-
The present invention aims to provide a prophylactic or therapeutic agent for schizophrenia and the like, containing the compound of the present invention having a GPR52 agonist activity. A compound represented by the following formula (I) or a salt there
- -
-
Page/Page column 70-71
(2011/04/18)
-
- N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
-
The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
- -
-
Page/Page column 115
(2010/12/29)
-
- Design and synthesis of new chiral pyridine-phosphite ligands for the copper-catalyzed enantioselective conjugate addition of diethylzinc to acyclic enones
-
A series of new chiral pyridine-phosphite ligands have been prepared from (R)-pyridyl alcohols and BINOL-derived chlorophosphite, and successfully employed in the copper-catalyzed enantioselective conjugate addition of diethylzinc to acyclic enones. Using the simple and inexpensive CuBr2 as a precursor, the enantioselective additions to various substituted acyclic enones afforded products in high yields and good enantioselectivities (up to 92% ee).
- Xie, Yinjun,Huang, Hanmin,Mo, Weimin,Fan, Xiangqun,Shen, Zhiqiang,Shen, Zhenlu,Sun, Nan,Hu, Baoxiang,Hu, Xinquan
-
experimental part
p. 1425 - 1432
(2009/12/04)
-